Seeking Alpha

Acura Pharmaceuticals (ACUR) says it's received notification from a generic sponsor of its...

Acura Pharmaceuticals (ACUR) says it's received notification from a generic sponsor of its filing of an Abbreviated New Drug Application for a generic version of Oxecta Tablets, saying it believes Acura's patents are invalid, unenforceable or not infringed. Pfizer (PFE) licenses Oxecta, but it's covered by U.S. patents issued to ACUR, who says it intends to take appropriate action to enforce its intellectual property.
Comments (1)
  • rvood
    , contributor
    Comment (1) | Send Message
     
    Figures with the way this stock and company have gone
    20 Sep 2012, 07:53 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|